MET and lung adenocarcinoma: The prevalence and type of mutations detected in our series of cytology samples are comparable to those reported by The National Cancer Institute Lung Cancer Mutation Consortium in 1,000 lung adenocarcinomas [40], which were: KRAS 25%, EGFR 23%, BRAF 3%, PIK3CA 3%, MET amplifications 2%, ERBB2 1%, MAP2K1 0.4%, and NRAS 0.2% [40].